IP Library Granted Patent US 11,453,642
Granted Patent B2
US 11,453,642 · App. 17/080,636 · Granted Sep 27, 2022

Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use

Inventors: Georg Schlechtingen (Dresden, DE); Hans-Joachim Knolker (Dresden, DE); Tim Friedrichson (Dresden, DE); Gary Jennings (Dresden, DE); Tobias Braxmeier (Kuppenheim, DE)
Assignee: GRI Bio, Inc.
C07C309/14A61K31/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,453,642
App. No.
17/080,636
Granted
Sep 27, 2022
Kind
B2
Abstract

The present invention relates to oxygenated amino and ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Claims (34)

1. A method of treating or ameliorating an inflammatory, autoimmune and/or allergic disorder, the method comprising the administration of a compound of formula 1 to a subject in need of such a treatment or amelioration, wherein the compound of formula 1 is

or a pharmaceutically acceptable salt thereof,

wherein

R 1 is a C 10-20 hydrocarbon group;

R 2 is a C 1-4 alkyl group, and R 3 is —H, or R 3 is absent;

R 4 is a C 3-6 alkylene group which is substituted with one or more groups independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), —O—C(O)—O(C 1-3 alkyl), —O—C(O)—NH 2 , —O—C(O)—NH(C 1-3 alkyl), —O—C(O)—N(C 1-3 alkyl)(C 1-3 alkyl), —O(CH 2 ) 2 OH, or —O(CH 2 ) 3 OH;

R 5 is —SO 3 − , —SO 3 H, —PO 3 H − , —PO 3 2− , —PO 3 H 2 , —PO 2 (OC 1-3 alkyl) − , —PO 2 H(OC 1-3 alkyl), —PO(OC 1-3 alkyl) 2 , —CO 2 —, —CO 2 H, or —CO 2 (C 1-3 alkyl); and

X is N + or, if R 3 is absent, X is N;

wherein said inflammatory, autoimmune and/or allergic disorder is selected from: psoriasis, atopic dermatitis (atopic eczema), contact dermatitis, xerotic eczema, seborrheic dermatitis, neurodermitis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis (Duhring's Disease), autoeczematization, dermatomyositis, hyper-IgE (Buckley) syndrome, Wiskott-Aldrich syndrome, anaphylaxis, food allergy, allergic reactions to venomous stings, acute urticarias, chronic urticarias, physical urticarias including aquagenic urticaria, cholinergic urticaria, cold urticaria (chronic cold urticaria), delayed pressure urticaria, dermatographic urticaria, heat urticaria, solar urticaria, vibration urticaria, adrenergic urticaria, urticaria angioedema, inflammatory bowel disease, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, diversion colitis (diverticulitis), Behçet's syndrome, indeterminate colitis, celiac disease, irritable bowel syndrome, post-operative ileus, eosinophilic gastroenteropathy, gastritis, chronic allergic rhinitis, seasonal allergic rhinitis (hay-fever), allergic conjunctivitis, chemical conjunctivitis, neonatal conjunctivitis, Sjögren syndrome, open-angle glaucoma, dry eye disease, diabetic macular edema, chronic obstructive pulmonary disease (COPD), allergic asthma, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, lung fibrosis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, reactive arthritis, polymyalgia rheumatica, multiple sclerosis, Guillain-Barre syndrome, Hashimoto's thyroiditis, Grave's disease, temporal arteritis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, alopecia areata, a graft-versus-host disease, a host-versus-graft disease, or a transplant rejection.

2. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from psoriasis, atopic dermatitis (atopic eczema), contact dermatitis, xerotic eczema, seborrheic dermatitis, neurodermitis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis (Duhring's Disease), autoeczematization, dermatomyositis, hyper-IgE (Buckley) syndrome, Wiskott-Aldrich syndrome, anaphylaxis, food allergy, or allergic reactions to venomous stings.

3. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from acute urticarias, chronic urticarias, physical urticarias including aquagenic urticaria, cholinergic urticaria, cold urticaria (chronic cold urticaria), delayed pressure urticaria, dermatographic urticaria, heat urticaria, solar urticaria, vibration urticaria, adrenergic urticaria, or urticaria angioedema.

4. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from inflammatory bowel disease, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, diversion colitis (diverticulitis), Behçet's syndrome, indeterminate colitis, celiac disease, irritable bowel syndrome, post-operative ileus, eosinophilic gastroenteropathy, or gastritis.

5. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from chronic allergic rhinitis, seasonal allergic rhinitis (hay-fever), allergic conjunctivitis, chemical conjunctivitis, neonatal conjunctivitis, Sjögren syndrome, open-angle glaucoma, dry eye disease, or diabetic macular edema.

6. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from chronic obstructive pulmonary disease (COPD), allergic asthma, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, or lung fibrosis.

7. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, reactive arthritis, or polymyalgia rheumatica.

8. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from multiple sclerosis, Guillain-Barre syndrome, Hashimoto's thyroiditis, Grave's disease, temporal arteritis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, or alopecia areata.

9. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from a graft-versus-host disease, a host-versus-graft disease or a transplant rejection.

10. The method of claim 1 , wherein said compound of formula 1 is administered in a pharmaceutical composition.

11. The method of claim 6 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 6 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 7 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2022
From: GRI BIO, INC.
To: ALTIUM GROWTH FUND, LP
Reel/Frame 062108/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2020
From: SCHLECHTINGEN, GEORG; KNOLKER, HANS-JOACHIM; FRIEDRICHSON, TIM; JENNINGS, GARY; BRAXMEIER, TOBIAS
To: GLYCOREGIMMUNE, INC.
Reel/Frame 054229/0732 →
CHANGE OF NAME Recorded Oct 30, 2020
From: GLYCOREGIMMUNE, INC.
To: GRI BIO, INC.
Reel/Frame 054269/0237 →
Priority Claims (1)
EP 11167731 · May 26, 2011 · regional
Continuity (3)
Continuation 15694303 · Sep 1, 2017
Continuation 14403168
Related Publication 20210114979A1 · Apr 22, 2021
Cited By (1)
US 12,528,775